Derma Sciences Inc expects to find a deep-pocketed partner for its treatment for diabetes-induced foot ulcers in the first half of 2012, even before it enrolls patients for late-stage trials. Derma Sciences specializes in products that treat wounds from common burns to deep skin gashes, with annual revenue of $56.5 million.
Its newest product, a topical gel dubbed DSC127, could reap over $1 billion in worldwide annual sales if approved, according to its chief executive. “We are fielding inquiries from a number of multinational pharmaceutical companies about DSC127,” CEO Edward Quilty told Reuters in an interview, without providing any details. “There is a high likelihood that the partnering will happen before we enroll the first patient in the Phase 3 trial.”
» Read more: Derma sees partner for new drug in first half 2012